QL1706 Plus Lenvatinib

DRUG2 trials

Sponsors

Qilu Pharmaceutical Co., Ltd., Northern Jiangsu People's Hospital

Conditions

Advanced Renal Cell CarcinomaHCC - Hepatocellular Carcinoma

Phase 1

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Qilu Pharmaceutical Co., Ltd.Advanced Renal Cell Carcinoma

Start: 2022-02-28End: 2024-07-30Target: 60Updated: 2022-03-02

Phase 2

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

Not yet recruitingNCT06884982

Northern Jiangsu People's HospitalHCC - Hepatocellular Carcinoma

Start: 2025-03-13End: 2028-09-30Target: 30Updated: 2025-03-19